PO Box 1488
Warrenville, IL 60555
Phone: 331.248.7888
Email: sidp@affinity-strategies.com
In this episode of Breakpoints’ Dosing Consult series, Drs. Chuck Peloquin and Gerry Davies join Dr. Megan Klatt to discuss rifampin dosing for mycobacterial infections. Hear from the experts on if higher doses are really better, toxicity thresholds, and the role of alternative rifamycins for patients with MTB and NTMs.
References:
- Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 Sep 1;198(5):657-666. doi: 10.1164/rccm.201712-2524OC.
- Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311.
- Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007 Oct; 2007(4): CD005159. doi: 10.1002/14651858.CD005159.pub2.
- Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease. Clin Infect Dis. 2023 Oct 5;77(7):1053-1062. doi: 10.1093/cid/ciad312.
Charles (Chuck) Peloquin, BS, PharmD, FCCP
Professor Chuck Peloquin received his Bachelor of Science in Pharmacy from the University of Connecticut and his Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science. He completed his residency at Duke University Medical Center, his fellowship in infectious diseases and pharmacokinetics at the Millard Fillmore Hospital in Buffalo, New York, and he currently serves as the Professor and Division Head Translational Research and as the Jack C. Massey Endowed Professor within the University of Florida College of Pharmacy. Professor Peloquin has been the Director of the Infectious Diseases Pharmacokinetics Laboratory, first at National Jewish Health in Denver, and for the past 14 years at the University of Florida. He is a contributor to the US. National TB Treatment Guidelines, the US National AIDS Opportunistic Infection Guidelines, selected WHO TB Treatment Guidelines, and the Curie International TB Center Drug Resistant TB Survival Guide. He has authored over 400 manuscripts, including over 250 original research articles, over 50 review articles, and over 50 book chapters.
Gerry Davies, BM, PhD, FRCP, DTM&H
Dr. Davies is a Professor of Infection Pharmacology, and Honorary Consultant in Infectious Diseases at the University of Liverpool. He is the TB Lead Clinician for Liverpool, and an Advisor to the British Thoracic Society MDR TB Clinical Advice Service.He obtained his Master of Science in Epidemiology from the London School of Hygiene, and a PhD in Pharmacology from the University of Liverpool. Since 2005, he has been an editor for the Cochrane Infectious Diseases Group, specializing in tuberculosis, and he has extensive experience of phase two and phase three clinical trials in tuberculosis in differing roles. He played a prominent role in the EU Innovative Medicines Initiative, Product Development Partnerships, Predict TB, and Unite for TB, and has served on numerous WHO policy task forces, guideline development groups, and technical advisory groups over the last decade related to the treatment of tuberculosis.
